Dihydroergotamine (injection): Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Dihydroergotamine}} | ||
{{CMG}}; {{AE}} {{PB}} | {{CMG}}; {{AE}} {{PB}} | ||
'''''For patient information about | '''''For patient information about Dihydroergotamine, click [[Dihydroergotamine (patient information)|here]].''''' | ||
{{SB}} | {{SB}} | ||
Line 33: | Line 33: | ||
|routes_of_administration= | |routes_of_administration= | ||
}} | }} | ||
'''Dihydroergotamine''' is an [[ergot]] alkaloid used to treat [[migraine]]s. | '''Dihydroergotamine''' is an [[ergot]] alkaloid used to treat [[migraine]]s. | ||
==Category== | ==Category== | ||
Line 46: | Line 40: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
==MIGRANAL (dihydroergotamine mesylate) spray Normal 0 false false false EN-US X-NONE X-NONE == | |||
''' [[MIGRANAL (dihydroergotamine mesylate) spray indications and usage|Indications and Usage]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray dosage and administration|Dosage and Administration]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray contraindications|Contraindications]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray adverse reactions|Adverse Reactions]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray drug interactions|Drug Interactions]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray use in specific populations|Use in Specific Populations]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray overdosage|Overdosage]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray description|Description]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray clinical studies|Clinical Studies]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray patient counseling information|Patient Counseling Information]]''' | |||
'''| [[MIGRANAL (dihydroergotamine mesylate) spray labels and packages|Labels and Packages]]''' | |||
==D.H.E. 45 (dihydroergotamine mesylate) injection, solution Normal 0 false false false EN-US X-NONE X-NONE == | |||
''' [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution indications and usage|Indications and Usage]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution dosage and administration|Dosage and Administration]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution contraindications|Contraindications]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution adverse reactions|Adverse Reactions]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution drug interactions|Drug Interactions]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution use in specific populations|Use in Specific Populations]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution overdosage|Overdosage]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution description|Description]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution clinical studies|Clinical Studies]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution patient counseling information|Patient Counseling Information]]''' | |||
'''| [[D.H.E. 45 (dihydroergotamine mesylate) injection, solution labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
'''Dihydroergotamine''' is an [[ergot]] alkaloid used to treat [[migraine]]s.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MIGRANAL (DIHYDROERGOTAMINE MESYLATE) SPRAY [VALEANT PHARMACEUTICALS INTERNATIONAL] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a24befa8-b952-48ac-942a-379585250782 | publisher = | date = | accessdate = }}</ref> | '''Dihydroergotamine''' is an [[ergot]] alkaloid used to treat [[migraine]]s.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MIGRANAL (DIHYDROERGOTAMINE MESYLATE) SPRAY [VALEANT PHARMACEUTICALS INTERNATIONAL] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a24befa8-b952-48ac-942a-379585250782 | publisher = | date = | accessdate = }}</ref> <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = D.H.E. 45 (DIHYDROERGOTAMINE MESYLATE) INJECTION, SOLUTION [VALEANT PHARMACEUTICALS NORTH AMERICA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe826e6a-75c8-43ed-9c36-f8263ec35aff | publisher = | date = | accessdate = }}</ref> Normal 0 false false false EN-US X-NONE X-NONE | ||
==References== | ==References== | ||
Line 80: | Line 92: | ||
[[pl:Dihydroergotamina]] | [[pl:Dihydroergotamina]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 22:10, 11 February 2014
Dihydroergotamine |
---|
MIGRANAL (dihydroergotamine mesylate) spray® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Dosage Forms and Strengths |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
Clinical Studies |
How Supplied/Storage and Handling |
Patient Counseling Information |
Labels and Packages |
Clinical Trials on Dihydroergotamine |
ClinicalTrials.gov |
Dihydroergotamine |
D.H.E. 45 (dihydroergotamine mesylate) injection, solution® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Dosage Forms and Strengths |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
Clinical Studies |
How Supplied/Storage and Handling |
Patient Counseling Information |
Labels and Packages |
Clinical Trials on Dihydroergotamine |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information about Dihydroergotamine, click here.
Synonyms / Brand Names:
Overview
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 9 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C33H37N5O5 |
Molar mass | 583.678 g/mol |
Dihydroergotamine is an ergot alkaloid used to treat migraines.
Category
FDA Package Insert
MIGRANAL (dihydroergotamine mesylate) spray Normal 0 false false false EN-US X-NONE X-NONE
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
D.H.E. 45 (dihydroergotamine mesylate) injection, solution Normal 0 false false false EN-US X-NONE X-NONE
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Dihydroergotamine is an ergot alkaloid used to treat migraines.[1] [1] Normal 0 false false false EN-US X-NONE X-NONE
References
- Pages with script errors
- Pages with reference errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs
- Lysergamides